Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Safety and Efficacy Study of Enpatoran in Lupus Participants Completing WILLOW
jRCT2071220084Phase 2Active, not recruiting
- Sponsor
- Merck KGaA
- Start
- Jan 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of enpatoran in systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), subacute cutaneous lupus erythematosus (SCLE) and 1 more (3 arms), sponsored by Merck KGaA. Primary endpoint: Occurrence of adverse events (TEAEs, SAEs, and AESIs). Started Jan 2023; status: active, not recruiting.
02
Drugs
enpatoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)subacute cutaneous lupus erythematosus (SCLE)discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on jRCT2071220084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220084.